194 related articles for article (PubMed ID: 28860588)
1. Synthetic lethality screens point the way to new cancer drug targets.
Mullard A
Nat Rev Drug Discov; 2017 Sep; 16(9):589-591. PubMed ID: 28860588
[No Abstract] [Full Text] [Related]
2. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
3. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality on drug discovery: an update on cancer therapy.
Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
[TBL] [Abstract][Full Text] [Related]
5. The role of drug-metabolizing enzymes in synthetic lethality of cancer.
Zeng Z; Zheng W; Hou P
Pharmacol Ther; 2022 Dec; 240():108219. PubMed ID: 35636517
[TBL] [Abstract][Full Text] [Related]
6. Complex synthetic lethality in cancer.
Ryan CJ; Devakumar LPS; Pettitt SJ; Lord CJ
Nat Genet; 2023 Dec; 55(12):2039-2048. PubMed ID: 38036785
[TBL] [Abstract][Full Text] [Related]
7. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality: emerging targets and opportunities in melanoma.
Thompson N; Adams DJ; Ranzani M
Pigment Cell Melanoma Res; 2017 Mar; 30(2):183-193. PubMed ID: 28097822
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
10. Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
Canaani D
Cancer Lett; 2014 Sep; 352(1):59-65. PubMed ID: 23962561
[TBL] [Abstract][Full Text] [Related]
11. Approaches to identifying synthetic lethal interactions in cancer.
Thompson JM; Nguyen QH; Singh M; Razorenova OV
Yale J Biol Med; 2015 Jun; 88(2):145-55. PubMed ID: 26029013
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
13. Network pharmacology for cancer drug discovery: are we there yet?
Azmi AS
Future Med Chem; 2012 May; 4(8):939-41. PubMed ID: 22650234
[No Abstract] [Full Text] [Related]
14. Marked for death: targeting epigenetic changes in cancer.
Pfister SX; Ashworth A
Nat Rev Drug Discov; 2017 Apr; 16(4):241-263. PubMed ID: 28280262
[TBL] [Abstract][Full Text] [Related]
15. Precision cancer medicine: where to target?
Yu Q; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
[No Abstract] [Full Text] [Related]
16. Synthetic lethality and cancer.
O'Neil NJ; Bailey ML; Hieter P
Nat Rev Genet; 2017 Oct; 18(10):613-623. PubMed ID: 28649135
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethal Interactions in Cancer Therapy.
Geng X; Wang X; Zhu D; Ying S
Curr Cancer Drug Targets; 2017; 17(4):304-310. PubMed ID: 27113746
[TBL] [Abstract][Full Text] [Related]
18. Scientists Journey Into Genomes Via CRISPR-Cas9.
Ricks D
J Natl Cancer Inst; 2015 Nov; 107(11):djv352. PubMed ID: 26538621
[No Abstract] [Full Text] [Related]
19. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
20. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
